These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 10868519)

  • 1. Platelet adhesion receptors: novel targets for anti-thrombotic therapy.
    Williamson D; Giuliano S; Jackson SP
    Aust N Z J Med; 1999 Jun; 29(3):452-61. PubMed ID: 10868519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ability of different glycoprotein IIb-IIIa ligands to support platelet aggregation induced by activating antibody CRC54.
    Naimushin YA; Mazurov AV
    Biochemistry (Mosc); 2005 Jul; 70(7):782-9. PubMed ID: 16097942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calpain regulation of cytoskeletal signaling complexes in von Willebrand factor-stimulated platelets. Distinct roles for glycoprotein Ib-V-IX and glycoprotein IIb-IIIa (integrin alphaIIbbeta3) in von Willebrand factor-induced signal transduction.
    Yuan Y; Dopheide SM; Ivanidis C; Salem HH; Jackson SP
    J Biol Chem; 1997 Aug; 272(35):21847-54. PubMed ID: 9268316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of monoclonal antibodies that inhibit platelet adhesion or aggregation as potential anti-thrombotic drugs.
    De Meyer SF; Vanhoorelbeke K; Ulrichts H; Staelens S; Feys HB; Salles I; Fontayne A; Deckmyn H
    Cardiovasc Hematol Disord Drug Targets; 2006 Sep; 6(3):191-207. PubMed ID: 17017902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. von Willebrand factor mediates platelet spreading through glycoprotein Ib and alpha(IIb)beta3 in the presence of botrocetin and ristocetin, respectively.
    McCarty OJ; Calaminus SD; Berndt MC; Machesky LM; Watson SP
    J Thromb Haemost; 2006 Jun; 4(6):1367-78. PubMed ID: 16706984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
    Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV
    Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet thrombus formation on collagen at high shear rates is mediated by von Willebrand factor-glycoprotein Ib interaction and inhibited by von Willebrand factor-glycoprotein IIb/IIIa interaction.
    Wu YP; Vink T; Schiphorst M; van Zanten GH; IJsseldijk MJ; de Groot PG; Sixma JJ
    Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1661-7. PubMed ID: 10845886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Essential role for phosphoinositide 3-kinase in shear-dependent signaling between platelet glycoprotein Ib/V/IX and integrin alpha(IIb)beta(3).
    Yap CL; Anderson KE; Hughan SC; Dopheide SM; Salem HH; Jackson SP
    Blood; 2002 Jan; 99(1):151-8. PubMed ID: 11756165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis.
    Abulencia JP; Tien N; McCarty OJ; Plymire D; Mousa SA; Konstantopoulos K
    Arterioscler Thromb Vasc Biol; 2001 Jan; 21(1):149-56. PubMed ID: 11145947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor--results from patients with acute myocardial infarction and healthy controls.
    Reininger AJ; Agneskirchner J; Bode PA; Spannagl M; Wurzinger LJ
    Thromb Haemost; 2000 Feb; 83(2):217-23. PubMed ID: 10739376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins.
    Tam SH; Sassoli PM; Jordan RE; Nakada MT
    Circulation; 1998 Sep; 98(11):1085-91. PubMed ID: 9736595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
    Matzdorff A; Voss R
    Thromb Res; 2006; 117(3):307-14. PubMed ID: 15894353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.
    Leclerc JR
    Crit Care Med; 2002 May; 30(5 Suppl):S332-40. PubMed ID: 12004256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties.
    Suzuki K; Sato K; Kamohara M; Kaku S; Kawasaki T; Yano S; Iizumi Y
    Biol Pharm Bull; 2002 Aug; 25(8):1006-12. PubMed ID: 12186399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
    Mascelli MA; Worley S; Veriabo NJ; Lance ET; Mack S; Schaible T; Weisman HF; Jordan RE
    Circulation; 1997 Dec; 96(11):3860-6. PubMed ID: 9403608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
    Nannizzi-Alaimo L; Alves VL; Phillips DR
    Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
    Ilveskero S; Lassila R
    Thromb Res; 2006; 117(3):291-7. PubMed ID: 15878612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycoprotein Ib-IX-mediated activation of integrin alpha(IIb)beta(3): effects of receptor clustering and von Willebrand factor adhesion.
    Arya M; López JA; Romo GM; Cruz MA; Kasirer-Friede A; Shattil SJ; Anvari B
    J Thromb Haemost; 2003 Jun; 1(6):1150-7. PubMed ID: 12871313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor.
    Frishman WH; Burns B; Atac B; Alturk N; Altajar B; Lerrick K
    Am Heart J; 1995 Oct; 130(4):877-92. PubMed ID: 7572600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic platelet anesthesia by glycoprotein IIb/IIIa complex antagonist and argatroban during in vitro extracorporeal circulation.
    Kanemitsu S; Nishikawa M; Onoda K; Shimono T; Shimpo H; Yazaki A; Tanaka K; Shiku H; Yada I
    J Thorac Cardiovasc Surg; 2003 Aug; 126(2):428-35. PubMed ID: 12928640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.